Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRP019
MIFTS: 57

Peripheral Nervous System Disease

Categories: Immune diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Peripheral Nervous System Disease

About this section

MalaCards integrated aliases for Peripheral Nervous System Disease:

Name: Peripheral Nervous System Disease 12 15 17
Peripheral Neuropathy 12 74 53 29 6 17 71
Peripheral Nervous System Diseases 43
Peripheral Nerve Disorders 42
Peripheral Nerve Disease 12
Neuropathy, Peripheral 39

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:574
ICD9CM 34 350-359.99
MeSH 43 D010523
SNOMED-CT 67 42658009
ICD10 32 G64
UMLS 71 C0031117 C1335029
Sources

Summaries for Peripheral Nervous System Disease

About this section
NINDS : 53 Peripheral neuropathy refers to the many conditions that involve damage to the peripheral nervous system, which sends signals between the brain and spinal cord and all other parts of the body. Neuropathy means damage to one or more nerves, especially the peripheral nerves. More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms and prognosis. Impaired function and symptoms depend on the type of nerves that are damaged. Symptoms of neuropathy range from mild to disabling and may include a loss of reflexes, problems feeling pain or changes in temperature, numbness and tingling, and pain that is often worse at night. Symptoms may develop over days, weeks, or years. In some cases, the symptoms improve on their own and may not require advanced care. Causes of neuropathy include: diabetes physical injury (trauma) vascular and blood problems autoimmune disorders nutritional or vitamin imbalances, alcoholism, and exposure to toxins certain chemotherapy drugs infections  Most instances of neuropathy are either acquired, meaning the neuropathy isn’t present from the beginning of life, or genetic.  Acquired neuropathies are either symptomatic (the result of another disorder or condition) or idiopathic (meaning it has no known cause).

MalaCards based summary : Peripheral Nervous System Disease, also known as peripheral neuropathy, is related to autoimmune peripheral neuropathy and rare peripheral neuropathy, and has symptoms including seizures, tremor and back pain. An important gene associated with Peripheral Nervous System Disease is NEFL (Neurofilament Light). The drugs Aztreonam and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and brain, and related phenotype is nervous system.

Disease Ontology : 12 A nervous system disease that affects the peripheral nervous system.

MedlinePlus : 42 Your peripheral nerves are the ones outside your brain and spinal cord. Like static on a telephone line, peripheral nerve disorders distort or interrupt the messages between the brain and the rest of the body. There are more than 100 kinds of peripheral nerve disorders. They can affect one nerve or many nerves. Some are the result of other diseases, like diabetic nerve problems. Others, like Guillain-Barre syndrome, happen after a virus infection. Still others are from nerve compression, like carpal tunnel syndrome or thoracic outlet syndrome. In some cases, like complex regional pain syndrome and brachial plexus injuries, the problem begins after an injury. Some people are born with peripheral nerve disorders. Symptoms often start gradually, and then get worse. They include Numbness Pain Burning or tingling Muscle weakness Sensitivity to touch Treatment aims to treat any underlying problem, reduce pain and control symptoms. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 74 Peripheral neuropathy, often shortened to neuropathy, is a general term describing disease affecting the... more...

Sources

Related Diseases for Peripheral Nervous System Disease

About this section

Diseases in the Peripheral Nervous System Disease family:

Autoimmune Disease of Peripheral Nervous System

Diseases related to Peripheral Nervous System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1414)
# Related Disease Score Top Affiliating Genes
1 autoimmune peripheral neuropathy 35.4 MPZ ICOSLG GJB1
2 rare peripheral neuropathy 35.1 NGLY1 NEFL IARS2
3 motor peripheral neuropathy 35.0 PMP22 NEFL GJB1
4 neuropathy, hereditary, with liability to pressure palsies 34.1 PMP22 NEFL MPZ GJB1
5 hypertrophic neuropathy of dejerine-sottas 33.8 PMP22 NEFL MPZ GJB1
6 chediak-higashi syndrome 33.8 SERPINA3 ICOSLG H2AC18 CCR6
7 charcot-marie-tooth disease, axonal, type 2b 33.5 NEFL MPZ GJB1
8 foot drop 33.5 PMP22 MPZ
9 neuropathy, congenital hypomyelinating, 1, autosomal recessive 33.4 PMP22 NEFL MPZ GJB1
10 charcot-marie-tooth disease and deafness 33.0 PMP22 NEFL MPZ GJB1
11 charcot-marie-tooth disease, axonal, type 2cc 33.0 NEFL MPZ GJB1
12 charcot-marie-tooth disease, x-linked dominant, 1 33.0 PMP22 MPZ GJB1
13 optic nerve disease 32.2 SERPINA3 NEFL MT-ND4 ICOSLG ERCC6 CRYAA
14 charcot-marie-tooth disease, demyelinating, type 1a 32.2 PMP22 NEFL MPZ GJB1
15 nervous system disease 32.2 SERPINA3 NGF ICOSLG H2AC18 ERCC6 EPRS1
16 autoimmune disease 32.0 MUSK INS ICOSLG CD40LG CCR6
17 plasma cell neoplasm 31.9 TTR SERPINA3 ICOSLG CD40LG
18 neuromuscular disease 31.9 SERPINA3 PMP22 NEFL MUSK MPZ ICOSLG
19 monoclonal gammopathy of uncertain significance 31.8 ICOSLG CD40LG CCR6
20 systemic scleroderma 31.8 INS ICOSLG H2AC18 CD40LG CCR6
21 diabetes mellitus, noninsulin-dependent 31.8 TTR SERPINA3 NGF INS ICOSLG H2AC18
22 exanthem 31.8 ICOSLG H2AC18 CD40LG CCR6
23 cataract 31.8 TTR INS IARS2 ERCC6 CRYAA CD40LG
24 autosomal recessive disease 31.8 SERPINA3 H2AC18 ERCC6 EPRS1 CRYAA CCR6
25 pulmonary disease, chronic obstructive 31.8 SERPINA3 INS ICOSLG H2AC18 EPRS1 CCR6
26 multiple sclerosis 31.7 NGF NEFL MPZ CD40LG CCR6 AQP4
27 autosomal dominant cerebellar ataxia 31.7 SERPINA3 H2AC18 ERCC6 CRYAA
28 central nervous system disease 31.7 TTR SERPINA3 NGF ICOSLG H2AC18 ERCC6
29 eye disease 31.7 SERPINA3 NGF MT-ND4 INS ICOSLG H2AC18
30 miller fisher syndrome 31.7 PMP22 MUSK CD40LG
31 myelitis 31.7 ICOSLG CD40LG CCR6 AQP4
32 amyotrophic lateral sclerosis 1 31.6 SERPINA3 NGF NEFL H2AC18 ERCC6 EPRS1
33 neuropathy 31.6 PMP22 NGF NEFL MT-ND4 MPZ IARS2
34 diabetes mellitus, insulin-dependent 31.6 INS ICOSLG H2AC18 CD40LG CCR6
35 charcot-marie-tooth disease, demyelinating, type 1b 31.6 PMP22 MPZ GJB1
36 chronic polyneuropathy 31.5 PMP22 GJB1 CD40LG
37 collagen disease 31.5 SERPINA3 ICOSLG H2AC18 CD40LG CCR6
38 demyelinating disease 31.5 SERPINA3 PMP22 NGF MPZ ICOSLG H2AC18
39 acute cystitis 31.5 INS H2AC18 CD40LG CCR6
40 mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 31.5 MT-ND4 INS IARS2 EPRS1
41 rheumatic disease 31.4 ICOSLG H2AC18 CD40LG CCR6
42 polyneuropathy 31.4 TTR PMP22 NGF MPZ INS GJB1
43 chickenpox 31.4 ICOSLG CD40LG CCR6
44 guillain-barre syndrome 31.4 PMP22 MPZ CD40LG
45 retinitis pigmentosa 31.4 TTR NGF MT-ND4 INS H2AC18 ERCC6
46 temporal arteritis 31.3 SERPINA3 CD40LG CCR6
47 respiratory failure 31.3 TTR SERPINA3 MUSK H2AC18
48 sensory peripheral neuropathy 31.3 PMP22 NGF MPZ GJB1 CD40LG
49 polyradiculoneuropathy 31.3 PMP22 MPZ ICOSLG CD40LG
50 pelizaeus-merzbacher disease 31.3 SERPINA3 PMP22 MPZ H2AC18 ERCC6

Graphical network of the top 20 diseases related to Peripheral Nervous System Disease:



Diseases related to Peripheral Nervous System Disease
Sources

Symptoms & Phenotypes for Peripheral Nervous System Disease

About this section

UMLS symptoms related to Peripheral Nervous System Disease:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, neuralgia, neurologic symptoms, atypical facial pain

MGI Mouse Phenotypes related to Peripheral Nervous System Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.36 AQP4 CCR6 CD40LG ERCC6 GJB1 INS
Sources

Drugs & Therapeutics for Peripheral Nervous System Disease

About this section

Drugs for Peripheral Nervous System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 558)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aztreonam Approved Phase 4 78110-38-0 5362041 5742832
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Ofloxacin Approved Phase 4 82419-36-1 4583
5
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
6
Histamine Approved, Investigational Phase 4 51-45-6 774
7
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
8
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
11
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
12
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
13
Racepinephrine Approved Phase 4 329-65-7 838
14
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
15
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
16
Zidovudine Approved Phase 4 30516-87-1 35370
17
Lopinavir Approved Phase 4 192725-17-0 92727
18
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
19
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
20
Nevirapine Approved Phase 4 129618-40-2 4463
21
Ethanol Approved Phase 4 64-17-5 702
22
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
23
Norepinephrine Approved Phase 4 51-41-2 439260
24
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
25
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
26
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
27
Tapentadol Approved Phase 4 175591-23-8 9838022
28
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
29
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
30
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
31
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
32
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
33
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
34
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
35 Anticholesteremic Agents Phase 4
36 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
37 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
38 Histamine H1 Antagonists Phase 4
39
Histamine Phosphate Phase 4 51-74-1 65513
40 Histamine H1 Antagonists, Non-Sedating Phase 4
41 Histamine Antagonists Phase 4
42 Anti-Allergic Agents Phase 4
43 Antimanic Agents Phase 4
44 Excitatory Amino Acid Antagonists Phase 4
45 Excitatory Amino Acids Phase 4
46 Angiotensin-Converting Enzyme Inhibitors Phase 4
47 Sympathomimetics Phase 4
48 Antipyretics Phase 4
49 Adrenergic Agonists Phase 4
50 Epinephryl borate Phase 4

Interventional clinical trials:

(show top 50) (show all 1043)
# Name Status NCT ID Phase Drugs
1 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
2 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
3 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
4 Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY Unknown status NCT00235222 Phase 4 stavudine
5 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Surgery in Patients With Suppurative or Gangrenous Appendicitis Unknown status NCT03380793 Phase 4 morinidazole
6 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease Unknown status NCT03391440 Phase 4 morinidazole
7 A Multicenter, Double-blind, Randomized, Placebo and Active-controlled Study of Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
8 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
9 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
10 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
11 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
12 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
13 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
14 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
15 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
16 An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
17 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
18 A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
19 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
20 Comparison of the Analgesic Effect of the Local Anesthetics Ropicacaine, Levobupivacaine, and Levobupivacaine + Epinephrin Via Interscalene Nerve Block in Patients Undergoing Shoulder Arthroscopy Under General Anesthesia Completed NCT02691442 Phase 4 Ropivacaine 0.75%;Levobupivacaine 0.5%;Levobupivacaine 0.5% + epinephrin 1/200000
21 Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide (Prialt®)- The Swedish Ziconotide Bolus Study Completed NCT01373983 Phase 4 Ziconotide
22 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
23 A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment Completed NCT01675531 Phase 4 Targin
24 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
25 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
26 Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy: A Randomized, Double Blind, Placebo Controlled, Multi Center Trial Completed NCT02923388 Phase 4 Injection Mecobalamin,;Tablet Pyridoxine hydrochloride;Intravenous normal saline 1 ml;Placebo pill
27 L-Arginine and Endothelial Dysfunction in Type 2 Diabetic Patients Completed NCT00902616 Phase 4
28 A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain Completed NCT00407511 Phase 4 Pregabalin
29 The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy by Comparing the Change of HRV Index & ANS Function:A 6month Multicenter, Randomized, Open Label Clinical Trial CANON Study Completed NCT02056366 Phase 4 α-lipoic acid
30 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
31 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
32 Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
33 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
34 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Without Comorbid Major Depressive Disorder Completed NCT00401258 Phase 4 duloxetine
35 Pilot Phase IV, Multicenter, Randomized, Open-label and Controlled Study to Assess the Evolution of Peripheral Body Fat Distribution After Switching From Zidovudine Containing Backbone to Truvada in HIV-1-infected Patients on HAART (RECOMB Study). Completed NCT00324649 Phase 4 Truvada;Zidovudine/lamivudine
36 Randomized Double-blind Study Comparing the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component Completed NCT01166048 Phase 4 Duloxetine;Duloxetine
37 Exploratory, Cross-sectional Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy Completed NCT01116817 Phase 4 Lumbar puncture (Lopinavir/ritonavir monotherapy);Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI)
38 Evaluation of Safety and Efficacy of Raltegravir/Darunavir Combination in Antiretroviral-Naive Patients Completed NCT00677300 Phase 4 Raltegravir;Darunavir;Ritonavir;Tenofovir/Emtricitabine
39 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
40 Comparison of the Steady State Pharmacokinetics of Nevirapine, Stavudine Plus Lamivudine in HIV Positive Ugandan Patients Taking Triomune 40 With the Pharmacokinetics of the Originator Products. Completed NCT00455585 Phase 4 nevirapine, stavudine, lamivudine
41 Randomised and Prospective Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens Completed NCT00994344 Phase 4 Darunavir/ritonavir;Lopinavir/ritonavir
42 A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
43 The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty: A Double-Blinded Randomized Controlled Trial Completed NCT00620828 Phase 4 Ropivicaine 0.5%
44 Effect of Myofascial Release on Electrophysiological and Clinical Measures of Pregnant Women With Carpal Tunnel Syndrome Completed NCT03802448 Phase 4
45 URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence Recruiting NCT03302299 Phase 4 Isoniazid 300 Mg ORAL TABLET;Pyridoxine 25 Mg Oral Tablet
46 Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
47 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial Enrolling by invitation NCT03271151 Phase 4 Cymbalta
48 Precision Spinal Cord Stimulation for Painful Diabetic Neuropathy Terminated NCT00487981 Phase 4
49 Phase 4 Study of Tapentadol vs Oxycodone in Neuropathic Pain Terminated NCT01458015 Phase 4 tapentadol, oxycodone
50 A Randomized, Double-Blind, Placebo-Controlled Trial Of The Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy Symptoms In Subjects With Advanced Colorectal Cancer Terminated NCT00380874 Phase 4 Pregabalin;Placebo

Search NIH Clinical Center for Peripheral Nervous System Disease

Cochrane evidence based reviews: peripheral nervous system diseases

Sources

Genetic Tests for Peripheral Nervous System Disease

About this section

Genetic tests related to Peripheral Nervous System Disease:

# Genetic test Affiliating Genes
1 Peripheral Neuropathy 29
Sources

Anatomical Context for Peripheral Nervous System Disease

About this section

MalaCards organs/tissues related to Peripheral Nervous System Disease:

40
Breast, Lung, Brain, Skin, Spinal Cord, Testes, Bone
Sources

Publications for Peripheral Nervous System Disease

About this section

Articles related to Peripheral Nervous System Disease:

(show top 50) (show all 17559)
# Title Authors PMID Year
1
Diagnosis and treatment of sciatica. 42
31744805 2019
2
The effect of exercise on cervical radiculopathy: A systematic review and meta-analysis. 42
31702624 2019
3
Ilioinguinal/iliohypogastric nerve block versus transversus abdominis plane block for pain management following inguinal hernia repair surgery: A systematic review and meta-analysis of randomized controlled trials. 42
31626118 2019
4
Cobalt toxic optic neuropathy and retinopathy: Case report and review of the literature. 61
32025592 2020
5
Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial. 61
31209630 2020
6
Cluster and Factor Analysis of Elements in Serum and Urine of Diabetic Patients with Peripheral Neuropathy and Healthy People. 61
31140035 2020
7
Study of the possible synergistic protective effects of Melatonin and Pregabalin in Vincristine induced peripheral neuropathy Wistar Albino rats. 61
31816326 2020
8
Pathogenesis of platinum-induced peripheral neurotoxicity: Insights from preclinical studies. 61
31865195 2020
9
A recurrent missense variant in HARS2 results in variable sensorineural hearing loss in three unrelated families. 61
31827252 2020
10
Cycle Training improves vascular function and neuropathic symptoms in patients with type 2 diabetes and peripheral neuropathy: A randomized controlled trial. 61
31899340 2020
11
Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy. 61
31837318 2020
12
A retrospective analysis of the prevalence and clinical outcomes of vitamin D deficiency in myeloma patients in tropical Australia. 61
31227990 2020
13
Tangier disease: update for 2020. 61
32022754 2020
14
Rare case: paraneoplastic syndrome affecting peripheral nerves, associated with anti-collapsin-response mediator protein-5 (anti-CRMP5) antibodies, as early manifestation of small cell lung cancer confined to a solitary lymph node without evidence of lung mass on routine CT thorax. 61
32033998 2020
15
Regional differences in cell-mediated immunity in people with diabetic peripheral neuropathy. 61
31557355 2020
16
Sural nerve biopsy in peripheral neuropathies: 30-year experience from a single center. 61
31650437 2020
17
Variability in the clinical diagnosis of diabetic peripheral neuropathy. 61
31208891 2020
18
[Peripheral neuropathy with hypervitaminosis B6 caused by self-medication]. 61
31796339 2020
19
Peripheral neuropathy: Clinical pearls for making the diagnosis: Erratum. 61
31990843 2020
20
Muscle fatigability in patients with type 2 diabetes: relation with long-term complications. 61
31670895 2020
21
Photobiomodulation increases cell viability via AKT activation in an in vitro model of diabetes induced by glucose neurotoxicity. 61
31222481 2020
22
The complexity of classifying ANCA-associated small-vessel vasculitis in actual clinical practice: data from a multicenter retrospective survey. 61
31385079 2020
23
Impact of caloric restriction on peripheral nerve injury-induced neuropathic pain during ageing in mice. 61
31610068 2020
24
Sensorimotor and pain-related alterations of the gray matter and white matter in Type 2 diabetic patients with peripheral neuropathy. 61
31663232 2020
25
HINT1 gene pathogenic variants: the most common cause of recessive hereditary motor and sensory neuropathies in Russian patients. 61
31848916 2020
26
Early life vincristine fails to prime developing pain pathways. 61
31958538 2020
27
Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients. 61
32036471 2020
28
A simple method of quantifying chemotherapy-induced peripheral neuropathy using PainVision PS-2100®. 61
31774247 2020
29
Protective effect of hydrogen sulfide on oxidative stress-induced neurodegenerative diseases. 61
31552888 2020
30
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. 61
32029509 2020
31
Ankle fusion following failed initial treatment of complex ankle fractures in neuropathic diabetics. 61
30772132 2020
32
Traditional Chinese medicine foot bath combined with acupoint massage for the treatment of diabetic peripheral neuropathy: A systematic review and meta-analysis of 31 RCTs. 61
31659861 2020
33
Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review. 61
31760541 2020
34
Permanent damage of the sciatic nerve in an 8-year-old girl with newly diagnosed type 1 diabetes. 61
30739577 2020
35
Visit-to-Visit HbA1c Variability Is Associated With Cardiovascular Disease and Microvascular Complications in Patients With Newly Diagnosed Type 2 Diabetes. 61
31727686 2020
36
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. 61
32031899 2020
37
Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. 61
32016790 2020
38
Autonomic Peripheral Neuropathy. 61
31996622 2020
39
Peripheral nerve conductions in relapsing remitting multiple sclerosis (RRMS) patients. 61
32029369 2020
40
The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. 61
32029635 2020
41
Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. 61
31865857 2020
42
Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial. 61
31901783 2020
43
IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness. 61
31588566 2020
44
Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems. 61
31758983 2020
45
Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study. 61
32028414 2020
46
Living With Charcot-Marie-Tooth, Charlie, and Change. 61
31834205 2020
47
Semi-Mechanism-Based Pharmacokinetic-Toxicodynamic Model of Oxaliplatin-Induced Acute and Chronic Neuropathy. 61
32028733 2020
48
Structure-Based Design of Novel Biphenyl Amide Antagonists of Human Transient Receptor Potential Cation Channel Subfamily M Member 8 Channels with Potential Implications in the Treatment of Sensory Neuropathies. 61
31850745 2020
49
Effect of hyperbaric oxygen on chemotherapy-induced neuropathy in male and female rats. 61
31503072 2020
50
Analgesic and antiallodynic activity of novel anticonvulsant agents derived from 3-benzhydryl-pyrrolidine-2,5-dione in mouse models of nociceptive and neuropathic pain. 61
31874144 2020
Sources

Variations for Peripheral Nervous System Disease

About this section

ClinVar genetic disease variations for Peripheral Nervous System Disease:

6 (show top 50) (show all 58) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;XX;inv(7)(q11.23q36.3)dninversion Pathogenic 267882
2 IARS2 NM_018060.4(IARS2):c.2726C>T (p.Pro909Leu)SNV Pathogenic 156553 rs587783070 1:220316451-220316451 1:220143109-220143109
3 NGLY1 NM_018297.4(NGLY1):c.1533_1536del (p.Asn511fs)deletion Pathogenic 548658 rs765211108 3:25770699-25770702 3:25729208-25729211
4 NEFL NM_006158.4(NEFL):c.64C>T (p.Pro22Ser)SNV Pathogenic/Likely pathogenic 14029 rs28928910 8:24813966-24813966 8:24956452-24956452
5 PMP2 NM_002677.5(PMP2):c.128T>A (p.Ile43Asn)SNV Likely pathogenic 243087 rs879253869 8:82357170-82357170 8:81444935-81444935
6 DNAJB5 NM_001135005.3(DNAJB5):c.43C>T (p.Pro15Ser)SNV Likely pathogenic 243086 rs774909609 9:34990670-34990670 9:34990673-34990673
7 SPTLC3 NM_018327.4(SPTLC3):c.448T>C (p.Trp150Arg)SNV Likely pathogenic 243088 rs755919784 20:13053048-13053048 20:13072400-13072400
8 CHRNG NM_005199.5(CHRNG):c.256C>T (p.Arg86Cys)SNV Likely pathogenic 397615 rs777219451 2:233405327-233405327 2:232540617-232540617
9 COX6A1 NM_004373.4(COX6A1):c.103+1G>CSNV Likely pathogenic 560368 rs377504835 12:120876033-120876033 12:120438230-120438230
10 LMNA NM_170707.4(LMNA):c.1634G>A (p.Arg545His)SNV Conflicting interpretations of pathogenicity 163878 rs142191737 1:156107470-156107470 1:156137679-156137679
11 NEB NM_001271208.2(NEB):c.21902C>T (p.Pro7301Leu)SNV Conflicting interpretations of pathogenicity 387835 rs367626762 2:152384038-152384038 2:151527524-151527524
12 NEB NM_001271208.2(NEB):c.16637G>A (p.Arg5546His)SNV Conflicting interpretations of pathogenicity 257765 rs201111610 2:152435919-152435919 2:151579405-151579405
13 ABCA4 NM_000350.3(ABCA4):c.203C>T (p.Pro68Leu)SNV Conflicting interpretations of pathogenicity 99113 rs62654397 1:94577093-94577093 1:94111537-94111537
14 DNM2 NM_001005360.2(DNM2):c.190G>A (p.Val64Ile)SNV Conflicting interpretations of pathogenicity 133978 rs144250390 19:10870442-10870442 19:10759766-10759766
15 LMNA NM_170707.4(LMNA):c.344A>T (p.Glu115Val)SNV Conflicting interpretations of pathogenicity 200932 rs794728588 1:156085053-156085053 1:156115262-156115262
16 SPTAN1 NM_001130438.3(SPTAN1):c.4039G>A (p.Asp1347Asn)SNV Conflicting interpretations of pathogenicity 207286 rs574740801 9:131367749-131367749 9:128605470-128605470
17 MEFV NM_000243.2(MEFV):c.2084A>G (p.Lys695Arg)SNV Conflicting interpretations of pathogenicity 2547 rs104895094 16:3293403-3293403 16:3243403-3243403
18 ABCA4 NM_000350.3(ABCA4):c.2588G>C (p.Gly863Ala)SNV Conflicting interpretations of pathogenicity 7879 rs76157638 1:94517254-94517254 1:94051698-94051698
19 KIF24 deletion Uncertain significance 243059 9:34280042-34296294 9:34280044-34296296
20 DYSF NM_001130987.2(DYSF):c.1449G>A (p.Met483Ile)SNV Uncertain significance 288879 rs146064054 2:71762219-71762219 2:71535089-71535089
21 MT-ND4 NC_012920.1:m.11896C>GSNV Uncertain significance 370054 rs1057516065 MT:11896-11896 MT:11896-11896
22 MYH14 NM_001145809.2(MYH14):c.1945+6G>ASNV Uncertain significance 374064 rs1057518869 19:50756016-50756016 19:50252759-50252759
23 KIFBP NM_015634.4(KIFBP):c.167_187dup (p.Asp56_Glu62dup)duplication Uncertain significance 397616 rs767103634 10:70748746-70748747 10:68988990-68988991
24 SBF2 NM_030962.3(SBF2):c.5014_5016del (p.Lys1672del)deletion Uncertain significance 397621 rs750958357 11:9809202-9809204 11:9787655-9787657
25 MKS1 NM_001165927.1(MKS1):c.1577G>A (p.Arg526Gln)SNV Uncertain significance 397617 rs746283445 17:56283513-56283513 17:58206152-58206152
26 PRX NM_020956.2(PRX):c.*2540G>ASNV Uncertain significance 397620 rs369505684 19:40901924-40901924 19:40396017-40396017
27 PNPLA6 NM_006702.5(PNPLA6):c.1088C>T (p.Ser363Leu)SNV Uncertain significance 397619 rs372193709 19:7606906-7606906 19:7542020-7542020
28 PHKA1 NM_002637.4(PHKA1):c.1272T>A (p.Asp424Glu)SNV Uncertain significance 397618 rs1060499719 X:71870292-71870292 X:72650442-72650442
29 FLRT1 NM_014067.4(MACROD1):c.517+34934G>CSNV Uncertain significance 461801 rs139768227 11:63883777-63883777 11:64116305-64116305
30 FLRT1 NM_014067.4(MACROD1):c.517+34743C>TSNV Uncertain significance 530937 rs770193280 11:63883968-63883968 11:64116496-64116496
31 FLRT1 NM_014067.4(MACROD1):c.517+33591C>TSNV Uncertain significance 530934 rs138289564 11:63885120-63885120 11:64117648-64117648
32 FLRT1 NM_014067.4(MACROD1):c.517+33852C>GSNV Uncertain significance 530941 rs138445479 11:63884859-63884859 11:64117387-64117387
33 FLRT1 NM_014067.4(MACROD1):c.517+33260C>ASNV Uncertain significance 530936 rs143309484 11:63885451-63885451 11:64117979-64117979
34 FLRT1 NM_014067.4(MACROD1):c.517+33192T>CSNV Uncertain significance 530940 rs150249733 11:63885519-63885519 11:64118047-64118047
35 FLRT1 NM_014067.4(MACROD1):c.517+34934G>ASNV Uncertain significance 530938 rs139768227 11:63883777-63883777 11:64116305-64116305
36 FLRT1 NM_014067.4(MACROD1):c.517+34449C>TSNV Uncertain significance 530935 rs148012979 11:63884262-63884262 11:64116790-64116790
37 MYBPC3 NM_000256.3(MYBPC3):c.3614G>A (p.Arg1205Gln)SNV Uncertain significance 181014 rs730880596 11:47354130-47354130 11:47332579-47332579
38 FLRT1 NM_014067.4(MACROD1):c.517+33243C>GSNV Uncertain significance 461796 rs140274429 11:63885468-63885468 11:64117996-64117996
39 FLRT1 NM_014067.4(MACROD1):c.517+34761C>GSNV Uncertain significance 530933 rs777177875 11:63883950-63883950 11:64116478-64116478
40 FLRT1 NM_014067.4(MACROD1):c.517+33617C>TSNV Uncertain significance 530939 rs150825004 11:63885094-63885094 11:64117622-64117622
41 FLRT1 NM_014067.4(MACROD1):c.517+34535G>ASNV Uncertain significance 579757 rs756250929 11:63884176-63884176 11:64116704-64116704
42 FLRT1 NM_014067.4(MACROD1):c.517+34898_517+34918deldeletion Uncertain significance 571356 rs1565240655 11:63883793-63883813 11:64116321-64116341
43 FLRT1 NM_014067.4(MACROD1):c.517+33881C>TSNV Uncertain significance 565723 rs767022154 11:63884830-63884830 11:64117358-64117358
44 FLRT1 NM_014067.4(MACROD1):c.517+34196G>ASNV Uncertain significance 566239 rs776773158 11:63884515-63884515 11:64117043-64117043
45 FLRT1 NM_014067.4(MACROD1):c.517+33719C>TSNV Uncertain significance 568577 rs769032516 11:63884992-63884992 11:64117520-64117520
46 FLRT1 NM_014067.4(MACROD1):c.517+33604C>ASNV Uncertain significance 566560 rs1395376914 11:63885107-63885107 11:64117635-64117635
47 FLRT1 NM_014067.4(MACROD1):c.517+34250T>ASNV Uncertain significance 577882 rs1565241569 11:63884461-63884461 11:64116989-64116989
48 FLRT1 NM_014067.4(MACROD1):c.517+33243C>TSNV Uncertain significance 575806 rs140274429 11:63885468-63885468 11:64117996-64117996
49 FLRT1 NM_014067.4(MACROD1):c.517+34305T>CSNV Uncertain significance 643512 11:63884406-63884406 11:64116934-64116934
50 FLRT1 NM_014067.4(MACROD1):c.517+34236G>ASNV Uncertain significance 647420 11:63884475-63884475 11:64117003-64117003

Copy number variations for Peripheral Nervous System Disease from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 107001 17 11200000 15900000 Copy number Peripheral neuropathy
Sources

Expression for Peripheral Nervous System Disease

About this section
Search GEO for disease gene expression data for Peripheral Nervous System Disease.
Sources

Pathways for Peripheral Nervous System Disease

About this section
Sources

GO Terms for Peripheral Nervous System Disease

About this section
Sources

Sources for Peripheral Nervous System Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....